

Citations

1. Van Wouwe JP. Carnitine deficiency during valproic acid treatment. *Int J Vitam Nutr Res* 1995;65:211-214.
2. Lamhonwah AM, Tein I. Carnitine uptake defect: frameshift mutations in the human plasmalemmal carnitine transporter gene. *Biochem Biophys Res Commun* 1998;252:396-401.
3. DiPalma JR. Carnitine deficiency. *Am Fam Physician* 1988;38:243-251.
4. Stumpf DA, Parker WD Jr, Angelini C. Carnitine deficiency, organic acidemias, and Reye's syndrome. *Neurology* 1985;35:1041-1045.
5. Del Favero A. Carnitine and gangliosides. *Lancet* 1988;2:337.
6. Tamamogullari N, Silig Y, Icagasioglu S, Atalay A. Carnitine deficiency in diabetes mellitus complications. *J Diabetes Complications* 1999;13:251-253.
7. Van Oudheusden LJ, Scholte HR. Efficacy of carnitine in the treatment of children with attention-deficit hyperactivity disorder. *Prostaglandins Leukot Essent Fatty Acids* 2002;67:33-38.
8. Rai G, Wright G, Scott L et al. Double-blind, placebo controlled study of acetyl-L-carnitine in patients with Alzheimer's dementia. *Curr Med Res Opin* 1990;11:638-647.
9. Benvenga S, Lakshmanan M, Trimarchi F. Carnitine is a naturally occurring inhibitor of thyroid hormone nuclear uptake. *Thyroid* 2000;10:1043-1050.
10. Benvenga S, Ruggeri RM, Russo A et al. Usefulness of L-carnitine, a naturally occurring peripheral antagonist of thyroid hormone action, in iatrogenic hyperthyroidism: a randomized, double-blind, placebo-controlled clinical trial. *J Clin Endocrinol Metab* 2001;86:3579-3594.
11. Bartels GL, Remme WJ, den Hartog FR et al. Additional antiischemic effects of long-term L-propionylcarnitine in anginal patients treated with conventional antianginal therapy. *Cardiovasc Drugs Ther* 1995;9:749-753.
12. Tepaske R, Velthuis H, Oudemans-van Straaten HM et al. Effect of preoperative oral immune-enhancing nutritional supplement on patients at high risk of infection after cardiac surgery: a randomised placebo-controlled trial. *Lancet* 2001;358:696-701.
13. Montgomery SA, Thal LJ, Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. *Int Clin Psychopharmacol* 2003;18:61-71.
14. Castro-Gago M, Lojo S, Novo I et al. Effects of chronic allopurinol therapy on purine metabolism in Duchenne muscular dystrophy. *Biochem Biophys Res Commun* 1987;147:152-157.
15. Borum PR, Broquist HP, Roelofs RJ. Muscle carnitine levels in neuromuscular disease. *J Neurol Sci* 1977;34:279-286.
16. Camina F, Novo-Rodriguez MI, Rodriguez-Segade S, Castro-Gago M. Purine and carnitine metabolism in muscle of patients with Duchenne muscular dystrophy. *Clin Chim Acta* 1995;243:151-164.
17. Willner JH, Ginsburg S, Dimauro S. Active transport of carnitine into skeletal muscle. *Neurology* 1978;28:721-724.
18. Rebouche CJ, Engel AG. Kinetic compartmental analysis of carnitine metabolism in the human carnitine deficiency syndromes: evidence for alterations in tissue carnitine transport. *J Clin Invest* 1984;73:857-867.
19. Abdel-aleem S, el-Merzabani MM, Sayed-Ahmed M et al. Acute and chronic effects of Adriamycin on fatty acid oxidation in isolated cardiac myocytes. *J Mol Cell Cardiol* 1997;29:789-797.
20. Mortensen SA, Olsen HS, Baandrup U. Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease. *Br Heart J* 1986;55:274-282.
21. Mortensen SA, Aabo K, Jonsson T, Baandrup U. Clinical and non-invasive assessment of anthracycline cardiotoxicity: perspectives on myocardial protection. *Int J Clin Pharmacol Res* 1986;6:137-150.
22. Steinhert LJ, Steinhert PG, Tan CT et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. *JAMA* 1991;266:1672-1677.
23. McFalls EO, Paulson DJ, Gilbert EF, Shug AL. Carnitine protection against Adriamycin-induced cardiomyopathy in rats. *Life Sci* 1986;38:497-505.
24. Neri B, Cini-Neri G, Bartalucci S, Bandinelli M. Protective effect of L-carnitine on cardiac metabolic damage induced by doxorubicin in vitro. *Anticancer Res* 1986;6:659-662.
25. Neri B, Neri GC, Bandinelli M. Differences between carnitine derivatives and coenzyme Q10 in preventing in vitro doxorubicin-related cardiac damages. *Oncology* 1988;45:242-246.
26. Alberts DS, Peng YM, Moon TE, Bressler R. Carnitine prevention of Adriamycin toxicity in mice. *Biomedicine* 1978;29:265-268.
27. Maccari F, Ramacci MT. Antagonism of doxorubicin cardiotoxicity by carnitine is specific of the L-diastereoisomer. *Biomedicine* 1981;35:65-67.
28. Sayed-Ahmed MM, Salman TM, Gaballah HE et al. Propionyl-L-carnitine as protector against Adriamycin-induced cardiomyopathy. *Pharmacol Res* 2001;43:513-520.

Citations and Reference Literature: Carnitine

29. Mijares A, Lopez JR. l-Carnitine prevents increase in diastolic [Ca²⁺] induced by doxorubicin in cardiac cells. *Eur J Pharmacol* 2001;425:117-120.
30. Brouwer CA, Gietema JA, van den Berg MP et al. Long-term cardiac follow-up in survivors of a malignant bone tumour. *Ann Oncol* 2006;17:1586-1591.
31. De Leonardis V, Neri B, Bacalli S, Cinelli P. Reduction of cardiac toxicity of anthracyclines by l-carnitine: preliminary overview of clinical data. *Int J Clin Pharmacol Res* 1985;5:137-142.
32. Chavez GA, Hernandez IM, Ollarve CF, Natera YM. Myocardial protection by l-carnitine in children treated with Adriamycin. *Rev Lat Cardiol* 1997;18:208-214.
33. Marsden JR, Trinick TR, Laker MF, Shuster S. Effects of isotretinoin on serum lipids and lipoproteins, liver and thyroid function. *Clin Chim Acta* 1984;143:243-251.
34. Laker MF, Green C, Bhuiyan AK, Shuster S. Isotretinoin and serum lipids: studies on fatty acid, apolipoprotein and intermediary metabolism. *Br J Dermatol* 1987;117:203-206.
35. Kim JY, Lee JJ, Kim KS. Acetyl-CoA carboxylase beta expression mediated by MyoD and muscle regulatory factor 4 is differentially affected by retinoic acid receptor and retinoid X receptor. *Exp Mol Med* 2003;35:23-29.
36. Georgala S, Schulpis KH, Georgala C, Michas T. l-Carnitine supplementation in patients with cystic acne on isotretinoin therapy. *J Eur Acad Dermatol Venereol* 1999;13:205-209.
37. Famularo G, Matricardi F, Nucera E et al. Carnitine deficiency: primary and secondary syndromes. In: De Simone C, Famularo G, eds. *Carnitine Today*. Austin, Texas: RG Landes; 1997.
38. Galland S, Georges B, Le Borgne F et al. Thyroid hormone controls carnitine status through modifications of gamma-butyrobetaine hydroxylase activity and gene expression. *Cell Mol Life Sci* 2002;59:540-545.
39. DeFelice SL, Gilgore SG. The antagonistic effect of carnitine in hyperthyroidism: preliminary report. *J New Drugs* 1966;6:351-353.
40. Benvenga S, Lapa D, Cannavo S, Trimarchi F. Successive thyroid storms treated with l-carnitine and low doses of methimazole. *Am J Med* 2003;115:417-418.
41. DeFelice SL, Kohl, H. *Carnitine Defense: a Nutraceutical Formula to Prevent and Treat Heart Disease*. Emmaus, Pa: Rodale Press; 1999.
42. Garzya G, Amico RM. Comparative study on the activity of racemic and laevorotatory carnitine in stable angina pectoris. *Int J Tissue Reactions* 1980;2:175-180.
43. Tishkin VS, Dunaev VV, Kryzhanovskii SA et al. [Study of anti-ischemic action of carnitine chloride and its effects on the effectiveness of antianginal agents]. *Kardiologiia* 1990;30:89-91.
44. McCarty MF. Management of acute myocardial infarction with natural physiological agents. *Med Hypotheses* 1983;11:449-465.
45. Cacciatore L, Cerio R, Ciarimboli M et al. The therapeutic effect of l-carnitine in patients with exercise-induced stable angina: a controlled study. *Drugs Exp Clin Res* 1991;17:225-235.
46. Inoue N, Hirata K, Akita H, Yokoyama M. Palmitoyl-l-carnitine modifies the function of vascular endothelium. *Cardiovasc Res* 1994;28:129-134.
47. Brass EP. Pivalate-generating prodrugs and carnitine homeostasis in man. *Pharmacol Rev* 2002;54:589-598.
48. Holme E, Greter J, Jacobson CE et al. Carnitine deficiency induced by pivampicillin and pivmecillinam therapy. *Lancet* 1989;2:469-473.
49. Diep QN, Bohmer T, Storrosten OT et al. [Slow replenishment of carnitine level after long-term treatment with pivampicillin/pivmecillinam]. *Tidsskr Nor Laegeforen* 1994;114:1614-1616.
50. Melegh B, Sumegi B, Sherry AD. Preferential elimination of pivalate with supplemental carnitine via formation of pivaloylcarnitine in man. *Xenobiotica* 1993;23:1255-1261.
51. Melegh B, Pap M, Molnar D et al. Carnitine administration ameliorates the changes in energy metabolism caused by short-term pivampicillin medication. *Eur J Pediatr* 1997;156:795-799.
52. Abrahamsson K, Eriksson BO, Holme E et al. Pivalic acid-induced carnitine deficiency and physical exercise in humans. *Metabolism* 1996;45:1501-1507.
53. Holme E, Jodal U, Linstedt S, Nordin I. Effects of pivalic acid-containing prodrugs on carnitine homeostasis and on response to fasting in children. *Scand J Clin Lab Invest* 1992;52:361-372.
54. Kahn J, Lagakos S, Wulfsohn M et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. *JAMA* 1999;282:2305-2312.
55. Sirtori CR, Calabresi L, Ferrara S et al. l-Carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a). *Nutr Metab Cardiovasc Dis* 2000;10:247-251.
56. Brescia F, Balestra E, Iasella MG, Damato AB. Effects of combined treatment with simvastatin and l-carnitine on triglyceride levels in diabetic patients with hyperlipidaemia. *Clin Drug Invest* 2002;22:23-28.

Citations and Reference Literature: Carnitine

57. Derosa G, Cicero AF, Gaddi A et al. The effect of l-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. *Clin Ther* 2003;25:1429-1439.
58. Solfrizzi V, Capurso C, Colacicco AM et al. Efficacy and tolerability of combined treatment with l-Carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus. *Atherosclerosis* 2006;188:455-461.
59. Burns MJ, Palmer BF. Valproic acid intoxication. In: Rose BD, ed. *UpToDate*. Wellesley, Mass: UpToDate; 2001.
60. Ater SB. A developmental center population treated with VPA and l-carnitine. Update 1993: inborn errors of metabolism in the patient with epilepsy. Sigma-Tau Pharmaceuticals; 1993.
61. Chung S, Choi J, Hyun T et al. Alterations in the carnitine metabolism in epileptic children treated with valproic acid. *J Korean Med Sci* 1997;12:553-558.
62. Dreifuss FE, Langer DH. Hepatic considerations in the use of antiepileptic drugs. *Epilepsia* 1987;28 Suppl 2:S23-S29.
63. Coulter DL. Carnitine deficiency: a possible mechanism for valproate hepatotoxicity. *Lancet* 1984;1:689.
64. Melegh B, Trombitas K. Valproate treatment induces lipid globule accumulation with ultrastructural abnormalities of mitochondria in skeletal muscle. *Neuropediatrics* 1997;28:257-261.
65. Morita J, Yuge K, Yoshino M. Hypocarnitinemia in the handicapped individuals who receive a polypharmacy of antiepileptic drugs. *Neuropediatrics* 1986;17:203-205.
66. Rodriguez-Segade S, de la Pena CA, Tutor JC et al. Carnitine deficiency associated with anticonvulsant therapy. *Clin Chim Acta* 1989;181:175-181.
67. Zelnik N, Fridnik I, Gruener N. Reduced carnitine and antiepileptic drugs: cause relationship or co-existence? *Acta Paediatr* 1995;84:93-95.
68. Castro-Gago M, Eiris-Punal J, Novo-Rodriguez MI et al. Serum carnitine levels in epileptic children before and during treatment with valproic acid, carbamazepine, and phenobarbital. *J Child Neurol* 1998;13:546-549.
69. Hug G, McGraw CA, Bates SR, Landrigan EA. Reduction of serum carnitine concentrations during anticonvulsant therapy with phenobarbital, valproic acid, phenytoin, and carbamazepine in children. *J Pediatr* 1991;119:799-802.
70. Verrotti A, Greco R, Morgese G, Chiarelli F. Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs. *Int J Clin Lab Res* 1999;29:36-40.
71. De Vivo DC, Bohan TP, Coulter DL et al. l-Carnitine supplementation in childhood epilepsy: current perspectives. *Epilepsia* 1998;39:1216-1225.
72. Hirose S, Mitsudome A, Yasumoto S et al. Valproate therapy does not deplete carnitine levels in otherwise healthy children. *Pediatrics* 1998;101:E9.
73. Hiraoka A, Arato T, Tominaga I. Reduction in blood free carnitine levels in association with changes in sodium valproate (VPA) disposition in epileptic patients treated with VPA and other anti-epileptic drugs. *Biol Pharm Bull* 1997;20:91-93.
74. Ohtani Y, Endo F, Matsuda I. Carnitine deficiency and hyperammonemia associated with valproic acid therapy. *J Pediatr* 1982;101:782-785.
75. Freeman JM, Vining EP, Cost S, Singhi P. Does carnitine administration improve the symptoms attributed to anticonvulsant medications? A double-blinded, crossover study. *Pediatrics* 1994;93:893-895.
76. Melegh B, Pap M, Morava E et al. Carnitine-dependent changes of metabolic fuel consumption during long-term treatment with valproic acid. *J Pediatr* 1994;125:317-321.
77. Gidal BE, Inglese CM, Meyer JF et al. Diet- and valproate-induced transient hyperammonemia: effect of l-carnitine. *Pediatr Neurol* 1997;16:301-305.
78. Sakemi K, Takada G. Effect of carnitine on valproic acid concentrations in serum, brain, and liver. *Pediatr Neurol* 1998;18:331-333.
79. Shuper A, Gutman A, Mimouni M. Intractable epilepsy. *Lancet* 1999;353:1238.
80. Houghton BL, Bowers JB. Valproic acid overdose: a case report and review of therapy. *MedGenMed* 2003;5:5.
81. Dalakas MC, Leon-Monzon ME, Bernardini I et al. Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage. *Ann Neurol* 1994;35:482-487.
82. Famularo G, De Simone C, Tzantzoglou S, Trinchieri V. Apoptosis, anti-apoptotic compounds and TNF-alpha release. *Immunol Today* 1994;15:495-496.
83. Campos Y, Arenas J. Muscle carnitine deficiency associated with zidovudine-induced mitochondrial myopathy. *Ann Neurol* 1994;36:680-681.
84. Semino-Mora MC, Leon-Monzon ME, Dalakas MC. The effect of l-carnitine on the AZT-induced destruction of human myotubes. Part II. Treatment with l-carnitine improves the AZT-induced changes and prevents further destruction. *Lab Invest* 1994;71:773-781.
85. Walker UA. Update on mitochondrial toxicity: where are we now? *J HIV Ther* 2003;8:32-35.

Citations and Reference Literature: Carnitine

86. De Simone C, Famularo G, Tzantzoglou S et al. Carnitine depletion in peripheral blood mononuclear cells from patients with AIDS: effect of oral l-carnitine. *AIDS* 1994;8:655-660.
87. Rossi L, Serafini S, Schiavano GF et al. Metabolism, mitochondrial uptake and toxicity of 2',3'-dideoxycytidine. *Biochem J* 1999;344 Pt 3:915-920.
88. Moretti S, Famularo G, Marcellini S et al. l-Carnitine reduces lymphocyte apoptosis and oxidant stress in HIV-1-infected subjects treated with zidovudine and didanosine. *Antioxid Redox Signal* 2002;4:391-403.
89. Semino-Mora MC, Leon-Monzon ME, Dalakas MC. Effect of l-carnitine on the zidovudine-induced destruction of human myotubes. Part I. l-Carnitine prevents the myotoxicity of AZT in vitro. *Lab Invest* 1994;71:102-112.
90. Kroemer G, Zamzami N, Susin SA. Mitochondrial control of apoptosis. *Immunol Today* 1997;18:44-51.
91. Moretti S, Alesse E, Di Marzio L et al. Effect of l-carnitine on human immunodeficiency virus-1 infection-associated apoptosis: a pilot study. *Blood* 1998;91:3817-3824.
92. Graziano F, Bissonni R, Catalano V et al. Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. *Br J Cancer* 2002;86:1854-1857.
93. Kalinec GM, Fernandez-Zapico ME, Urrutia R et al. Pivotal role of Harakiri in the induction and prevention of gentamicin-induced hearing loss. *Proc Natl Acad Sci USA* 2005;102:16019-16024.
94. Ferro M, Crivello R, Gianotti A, Conti M. [Treatment of hypertrophic cardiomyopathy with a combination of carnitine and beta blockers: review of the literature. Description of a clinical case and long-term follow up]. *Clin Ter* 1993;143:109-113.
95. Hagen TM, Liu J, Lykkesfeldt J et al. Feeding acetyl-l-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. *Proc Natl Acad Sci U S A* 2002;99:1870-1875.

Reference Literature

- [No authors listed.] [The National Board of Health and Welfare's warning: antibiotics containing pivalic acid cause carnitine deficiency.] *Lakartidningen* 1990;87(30-31):2436. [Swedish]
- [No authors listed.] [Antibiotics containing pivalic acid and carnitine deficiency: a report of the present status: therapeutic recommendations.] *Lakartidningen* 1991;88(30-31):2543. [Swedish]
- Abdel-Aziz MT, Abdou MS, Soliman K, et al. Effect of carnitine on blood lipid pattern in diabetic patients. *Nutr Rep Int* 1984;29:1071-1079.
- Alesci S, De Martino MU, Mirani M, et al. L-carnitine: A nutritional modulator of glucocorticoid receptor functions. *FASEB J* 2003;17(11):1553-1555.
- Anand I, Chandrashenkan Y, De Giuli F, et al. Acute and chronic effect of propionyl-L-carnitine on the hemodynamics, exercise capacity and hormones of patients with congestive heart failure. *Cardiovasc Drugs Ther* 1998;12:291-299.
- Barker GA, Green S, Askew CD, et al. Effect of propionyl-L-carnitine on exercise performance in peripheral arterial disease. *Med Sci Sports Exerc* 2001;33(9):1415-1422.
- Bartel LL, Hussey JL, Shrago E. Effect of dialysis on serum carnitine, free fatty acids, and triglyceride levels in man and the rat. *Metabolism* 1982;31(9):944-947.
- Bartels GL, Remme WJ, Holwerda KJ, et al. Anti-ischaemic efficacy of L-propionylcarnitine: a promising novel metabolic approach to ischaemia? *Eur Heart J* 1996;17(3):414-420.
- Bartels GL, Remme WJ, Pillay M, et al. Acute improvement of cardiac function with intravenous L-propionylcarnitine in humans. *J Cardiovasc Pharmacol* 1992;20(1):157-164.
- Bartels GL, Remme WJ, Pillay M, et al. Effects of L-propionylcarnitine on ischemia-induced myocardial dysfunction in men with angina pectoris. *Am J Cardiol* 1994;74(2):125-130.
- Beers MH, Berkow R, eds. *The Merck manual of diagnosis and therapy*. 17th ed. Whitehouse Station, NJ: Merck and Co, Inc; 1999, 881-883.
- Bella R, Biondi R, Raffaele R, et al. Effect of acetyl-L-carnitine on geriatric patients suffering from dysthymic disorders. *Int J Clin Pharmacol Res* 1990;10(6):355-360.
- Bertorini TE, Palmieri GM, Griffin J, et al. Chronic allopurinol and adenine therapy in Duchenne muscular dystrophy: effects on muscle function, nucleotide degradation, and muscle ATP and ADP content. *Neurology* 1985;35(1):61-65.
- Beverdorf D, Allen C, Nordgren R. Valproate induced encephalopathy treated with carnitine in an adult. *J Neurol Neurosurg Psychiatry* 1996;61(2):211.
- Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. *BJU Int* 2001;88(1):63-67.

Citations and Reference Literature: Carnitine

- Bianchetti A, Rozzini R, Trabucchi M. Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors. *Curr Med Res Opin* 2003;19(4):350-353.
- Bohles H, Lehnert W. The effect of intravenous L-carnitine on propionic acid excretion in acute propionic acidaemia. *Eur J Pediatr* 1984;143(1):61-63.
- Bohmer T, Endresen L. [Pivampicillin (Pondocillin) and pivmecillinam (Selexid) can result in carnitine deficiency.] *Tidsskr Nor Lægeforen* 1990;110(16):2090-2091. [Norwegian] (Review)
- Bolognesi M, Amodio P, Merkel C, et al. Effect of 8-day therapy with propionyl-L-carnitine on muscular and subcutaneous blood flow of the lower limbs in patients with peripheral arterial disease. *Clin Physiol* 1995;15(5): 417-423.
- Bonavita E. Study of the efficacy and tolerability of L-acetylcarnitine therapy in the senile brain. *Int J Clin Pharmacol Ther Toxicol* 1986;24:511-516.
- Bordin D, Bottecchia D, Bettini V, et al. Effect of middle-intensity exercise on carnitine and beta-hydroxybutyrate plasmatic concentration in men and women. *J Sports Med Phys Fitness* 1992;32(4):394-399.
- Bratton SL, Garden AL, Bohan TP, et al. A child with valproic acid-associated carnitine deficiency and carnitine-responsive cardiac dysfunction. *J Child Neurol* 1992;7(4):413-416.
- Brevetti G, Attisano T, Perna S, et al. Effect of L-carnitine on the reactive hyperemia in patients affected by peripheral vascular disease: a double-blind, crossover study. *Angiology* 1989;40:857-862.
- Brevetti G, Perna S, Sabba C, et al. Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. *J Am Coll Cardiol* 1995;26(6):1411-1416.
- Brevetti G, Chiariello M, Ferulano G, et al. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. *Circulation* 1988;77(4):767-773.
- Brevetti G, Diehm C, Lambert D. European multicenter study on propionyl-L-carnitine in intermittent claudication. *J Am Coll Cardiol* 1999;34(5):1618-1624.
- Brevetti G, Perna S, Sabba C, et al. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. *Eur Heart J* 1992;13(2):251-255.
- Brooks JO III, Yesavage JA, Carta A, et al. Acetyl L-carnitine slows decline in younger patients with Alzheimer's disease: a reanalysis of a double-blind, placebo-controlled study using the trilinear approach. *Int Psychogeriatr* 1998;10(2):193-203.
- Cacciatore L, Cerio R, Ciarimboli M, et al. The therapeutic effect of L-carnitine in patients with exercise-induced stable angina: a controlled study. *Drugs Exp Clin Res* 1991;17(4):225-235.
- Calabrese V, Scapagnini G, Catalano C, et al. Effects of acetyl-L-carnitine on the formation of fatty acid ethyl esters in brain and peripheral organs after short-term ethanol administration in rat. *Neurochem Res* 2001;26(2):167-174.
- Calvani M, Carta A, Caruso G, et al. Action of acetyl-L-carnitine in neurodegeneration and Alzheimer's disease. *Ann N Y Acad Sci* 1992;663:483-486.
- Camina MF, Rozas I, Gomez M, et al. Short-term effects of administration of anticonvulsant drugs on free carnitine and acylcarnitine in mouse serum and tissues. *Br J Pharmacol* 1991;103:1179-1183.
- Campaniello E, Petrarolo N, Meriggiola MC, et al. Carnitine administration in asthenospermia. The 4th International Congress of Andrology. Florence, Italy, May 14, 1989.
- Campi N, Todeschini GP, Scarzella L. Selegiline versus L-acetylcarnitine in the treatment of Alzheimer-type dementia. *Clin Ther* 1990;12(4):306-314.
- Campistol J, Chavez B, Vilaseca MA, et al. [Antiepileptic drugs and carnitine.] *Rev Neurol* 2000;30(Suppl 1):S105-S109. [Spanish]
- Capecchi PL, Laghi Pasini F, Quartarolo E, et al. Carnitines increase plasma levels of adenosine and ATP in humans. *Vasc Med* 1997;2(2):77-81.
- Caponnetto S, Canale C, Masperone MA, et al. Efficacy of L-propionylcarnitine treatment in patients with left ventricular dysfunction. *Eur Heart J* 1994;15:1267-1273.
- Castiglione A, Cornelio F, Vendemia F, et al. [Acute recurrent renal insufficiency in a patient with atraumatic rhabdomyolysis caused by carnitine-palmitoyltransferase deficiency.] *Minerva Nefrol* 1981;28(3):229-234. [Italian]
- Castro-Gago M, Camina F, Rodriguez-Segade S. Carnitine deficiency caused by valproic acid. *J Pediatr* 1992;120(3):496. (Letter)
- Cavallini G, Biagiotti G, Koverech A, et al. Oral propionyl-L-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease. *BJU Int* 2002;89:895-900.
- Cavallini G, Caracciolo S, Vitali G, et al. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. *Urology* 2004;63(4):641-646.
- Cherchi A, Lai C, Angelino F, et al. Effects of L-carnitine on exercise tolerance in chronic stable angina: a multicenter, double-blind, randomized, placebo controlled crossover study. *Int J Clin Pharmacol Ther Toxicol* 1985;23:569-572.

Citations and Reference Literature: Carnitine

- Cifone MG, Alesse E, Di Marzio L, et al. Effect of L-carnitine treatment in vivo on apoptosis and ceramide generation in peripheral blood lymphocytes from AIDS patients. *Proc Assoc Am Physicians* 1997;109(2):146-153.
- Cipolli C, Chiari G. Effects of L-acetylcarnitine on mental deterioration in the aged: initial results. *Clin Ter* 1990;132:479-510. [Italian; English abstract]
- Columbani P, Wenk C, Kunz I, et al. Effect of L-carnitine supplementation on physical performance and energy metabolism of endurance-trained athletes: a double blind crossover field study. *Eur J Appl Physiol* 1996;73:434-439.
- Costa M, Canale D, Filicori M, et al. L-carnitine in idiopathic asthenozoospermia: a multicenter study: Italian Study Group on Carnitine and Male Infertility. *Andrologia* 1994;26(3):155-159.
- Coulter DL. Carnitine deficiency in epilepsy: risk factors and treatment. *J Child Neurol* 1995;10(Suppl 2):S32-S39.
- Coulter DL. Carnitine, valproate, and toxicity. *J Child Neurol* 1991;6(1):7-14. (Review)
- Dal Lago A, De Martini D, Flore R, et al. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial. *Drugs Exp Clin Res* 1999;25(1):29-36.
- Dal Negro R, Pomari G, Zoccatelli O, et al. L-carnitine and rehabilitative respiratory physiokinesitherapy: metabolic and ventilatory response in chronic respiratory insufficiency. *Int J Clin Pharmacol Ther Toxicol* 1986;24:453-456.
- Dal Negro R, Turco P, Pomari C, et al. Effects of L-carnitine on physical performance in chronic respiratory insufficiency. *Int J Clin Pharmacol* 1988;26:269-272.
- Dal Negro R, Zoccatelli D, Pomari C, et al. L-carnitine and physiokinesiotherapy in chronic respiratory insufficiency: preliminary results. *Clin Trials J* 1985;22:353-360.
- Dal Negro R, Turco P, Pomari C, et al. Effects of L-carnitine on physical performance in chronic respiratory insufficiency. *Int J Clin Pharmacol Ther Toxicol* 1988;26:269-272.
- Davini P, Bigalli A, Lamanna F, et al. Controlled study on L-carnitine therapeutic efficacy in post-infarction. *Drugs Exp Clin Res* 1992;18(8):355-365.
- Dean SM. Pharmacologic treatment for intermittent claudication. *Vasc Med* 2002;7(4):301-309. (Review)
- Deckert J. Propionyl-L-carnitine for intermittent claudication. *J Fam Pract* 1997;44(6):533-534.
- Del Favero A. Carnitine and gangliosides. *Lancet* 1988;2:337. (Letter)
- De Simone C, Famularo G, eds. Carnitine today. Austin, TX: RG Landes; 1997.
- Diep QN, Bohmer T, Holme JI, et al. Slow replenishment of carnitine deficiency after cessation of long-term treatment with pivaloyl-containing antibiotics. *Pharm World Sci* 1993;15(5):225-259.
- Diep QN, Brors O, Bohmer T. Formation of pivaloylcarnitine in isolated rat heart cells. *Biochim Biophys Acta* 1995;1259(2):161-165.
- Diep QN, Bohmer T, Schjerven L. Reduced carnitine and ketogenesis in the pivampicillin treated rat. *Biochem Pharmacol* 1992;44(6):1226-1228.
- Digiesi V, Palchetti R, Cantini F. The benefits of L-carnitine in essential arterial hypertension. *Minerva Med* 1989;80:227-231.
- Di Marzio L, Alesse E, Roncaioli P, et al. Influence of L-carnitine on CD95 cross-linking-induced apoptosis and ceramide generation in human cell lines: correlation with its effects on purified acidic and neutral sphingomyelinases in vitro. *Proc Assoc Am Physicians* 1997;109(2):154-163.
- Di Marzio L, Moretti S, D'Alo S, et al. Acetyl-L-carnitine administration increases insulin-like growth factor 1 levels in asymptomatic HIV-1-infected subjects: correlation with its suppressive effect on lymphocyte apoptosis and ceramide generation. *Clin Immunol* 1999;92(1):103-110.
- Dipalma JR. Carnitine deficiency. *Am Fam Physician* 1988;38:243-251.
- Duncker DJ, Sassen LM, Bartels GL, et al. L-propionylcarnitine does not affect myocardial metabolic or functional response to chronotropic and inotropic stimulation after repetitive ischemia in anesthetized pigs. *J Cardiovasc Pharmacol* 1993;22(3):488-498.
- Engel AG, Bancker BQ, Eiben RM. Carnitine deficiency: clinical morphological and biochemical observations in a fatal case. *J Neurol Neurosurg Psychiatry* 1977;40:313.
- Famularo G, Moretti S, Marcellini S, et al. Cellular dysmetabolism: the dark side of HIV-1 infection. *J Clin Lab Immunol* 1996;48(3):123-132. (Review)
- Famularo G, Moretti S, Marcellini S, et al. Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues. *AIDS* 1997;11(2):185-190.
- Ferraresi R, Troiano L, Roat E, et al. Protective effect of acetyl-L-carnitine against oxidative stress induced by antiretroviral drugs. *FEBS Lett* 2006;580(28-29):6612-6616.
- Fosslien E. Review: mitochondrial medicine: cardiomyopathy caused by defective oxidative phosphorylation. *Ann Clin Lab Sci* 2003;33(4):371-395. (Review)

Citations and Reference Literature: Carnitine

- Fugh-Berman A. Herbs and dietary supplements in the prevention and treatment of cardiovascular disease. *Prev Cardiol* 2000;3(1): 24-32. (Review)
- Garzya G, Corallo D, Fiore A, et al. Evaluation of the effects of L-acetylcarnitine on senile patients suffering from depression. *Drugs Exp Clin Res* 1990;16:101-106.
- Garzya G, Amico RM. Comparative study on the activity of racemic and laevorotatory carnitine in stable angina pectoris. *Int J Tissue Reactions* 1980;2:175-180.
- Giamberardino MA, Dragani L, Valente R, et al. Effects of prolonged L-carnitine administration on delayed muscle pain and CK release after eccentric effort. *Int J Sports Med* 1996;17(5):320-324.
- Ghidini O, Azzurro M, Vita G, et al. Evaluation of the therapeutic efficacy of L-carnitine in congestive heart failure. *Int J Clin Pharmacol Ther Toxicol* 1988;26(4):217-220. Erratum in *Int J Clin Pharmacol Ther Toxicol* 1989;27(8):418.
- Giamberardino MA, Dragani L, Valente R, et al. Effects of prolonged L-carnitine administration on delayed muscle pain and CK release after eccentric effort. *Int J Sports Med* 1996;17:320-324.
- Gidal BE, Inglese CM, Meyer JF, et al. Diet-and valproate-induced transient hyperammonemia: effect of L-carnitine. *Pediatr Neurol* 1997;16(4):301-305.
- Giovannini M, Agostoni C, Salari PC. Is carnitine essential in children? *J Int Med Res* 1991;19:88-102.
- Greco AV, Mingrone G, Bianchi M, et al. Effect of propionyl-L-carnitine in the treatment of diabetic angiopathy: controlled double-blind trial versus placebo. *Drugs Exp Clin Res* 1992;18(2):69-80.
- Green RE, Levine AM, Gunning MJ. The effect of L-carnitine supplementation on lean body mass in male amateur body builders. *J Am Diet Assoc* 1997;(Suppl):A-72.
- Heinonen OJ. Carnitine and physical exercise. *Sports Med* 1996;22(2):109-132.
- Hiatt WR, Regensteiner JG, Creager MA, et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. *Am J Med* 2001;110(8):616-622.
- Iliceto S, Scrutinio D, Bruzzi P, et al. Effect of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. *J Am Coll Cardiol* 1995;26:380-387.
- Iyer R, Gupta A, Khan A, et al. Does left ventricular function improve with L-carnitine after acute myocardial infarction? *J Postgrad Med* 1999;45:38-41.
- Iyer RN, Khan AA, Gupta A, et al. L-carnitine moderately improves the exercise tolerance in chronic stable angina. *J Assoc Physicians India* 2000;48(11):1050-1052.
- Kelly GS. Insulin resistance: lifestyle and nutritional interventions. *Altern Med Rev* 2000;5(2):109-132. (Review)
- Kelley RI. The role of carnitine supplementation in valproic acid therapy. *Pediatr* 1994;93(6 Pt 1):891-892. (Editorial)
- Kendler BS. Carnitine: an overview of its role in preventive medicine. *Prev Med* 1986;15:373-390. (Review)
- Kerns W II, Kline J, Ford MD. Blocker and calcium channel blocker toxicity. *Emerg Med Clin North Am* 1994;12:2:365-390.
- Kobayashi A, Masumura Y, Yamazaki N. L-carnitine treatment for congestive heart failure: experimental and clinical study. *Jpn Circ J* 1992;56:86-94.
- Kraemer WJ, Volek JS, French DN, et al. The effects of L-carnitine L-tartrate supplementation on hormonal responses to resistance exercise and recovery. *J Strength Cond Res* 2003;17(3):455-462.
- Lagioia R, Scrutinio D, Mangini SG, et al. Propionyl-L-carnitine: a new compound in the metabolic approach to the treatment of effort angina. *Int J Cardiol* 1992;34:167-172.
- Larsen H, Nielsen GL, Sorensen HT, et al. A follow-up study of birth outcome in users of pivampicillin during pregnancy. *Acta Obstet Gynecol Scand* 2000;79(5):379-83.
- Lefkowitz RJ, Hoffman BB, Taylor P. Neurotransmission: the autonomic and somatic motor nervous systems. In: Hardman JG, Limbird LE, Molinoff PB, et al, eds. *Goodman & Gilman's the pharmacological basis of therapeutics*, 9th ed. New York: McGraw-Hill; 1996:105-139.
- Lenzi A, Lombardo F, Sgro P, et al. Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial. *Fertil Steril* 2003;79:292-300.
- Liu J, Head E, Gharib AM, et al. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha -lipoic acid. *Proc Natl Acad Sci U S A* 2002;99(4):2356-2361.
- Loster H, Mieke K, Punzel M, et al. Prolonged oral L-carnitine substitution increases bicycle ergometer performance in patients with severe, ischemically induced cardiac insufficiency. *Cardiovasc Drugs Ther* 1999;13:537-546.
- Loumbakis P, Anezinis P, Evangeliou A, et al. Effect of L-carnitine in patients with asthenospermia. *Eur Urol* 1996;30(Suppl 2):255. (Abstract)

Citations and Reference Literature: Carnitine

- Lowitt S, et al. Acetyl-L-carnitine corrects the altered peripheral nerve function of experimental diabetes. *Metabolism* 1995;44(5): 677-680.
- Mancini M, Rengo F, Lingetti M, et al. Controlled study on the therapeutic efficacy of propionyl-L-carnitine in patients with congestive heart failure. *Arzneimittelforschung* 1992;42:1101-1104.
- Mangano NG, Clementi G, Costantino G, et al. Effect of acetyl-L-carnitine on ethanol consumption and alcohol abstinence syndrome in rats. *Drugs Exp Clin Res* 2000;26(1):7-12.
- Marz R. Medical nutrition from Marz. 2nd ed. Portland, OR: Omni Press; 1997.
- Matsuda I, Ohtani Y. Carnitine status in Reye and Reye-like syndromes. *Pediatr Neurol* 1986;2:90-94.
- Mazzocchio R, Schieppati M, Scarpini C, et al. Enhancement of recurrent inhibition by intravenous administration of L-acetylcarnitine in spastic patients. *J Neurol Neurosurg Psychiatry* 1990;53(4):321-326.
- McCarty MF. Management of acute myocardial infarction with natural physiological agents. *Med Hypotheses* 1983;11(4):449-465. (Review)
- Melegh B. Carnitine supplementation in pivampicillin treatment. *Lancet* 1989;2(8671):1096.
- Melegh B, Jaszai V. Carnitine content of red blood cells of human subjects treated with pivampicillin and carnitine. *Acta Paediatr Hung* 1991;31(2):255-261.
- Melegh B, Kerner J, Bieber LL. Pivampicillin-promoted excretion of pivaloylcarnitine in humans. *Biochem Pharmacol* 1987;36(20): 3405-3409.
- Melegh B, Kerner J, Jaszai V, et al. Differential excretion of xenobiotic acyl-esters of carnitine due to administration of pivampicillin and valproate. *Biochem Med Metab Biol* 1990;43(1):30-38.
- Melegh B, Pap M, Bock I, et al. Relationship of carnitine and carnitine precursors lysine, epsilon-N-trimethyllysine, and gamma-butyrobetaine in drug-induced carnitine depletion. *Pediatr Res* 1993;34(4):460-464.
- Melegh B, Pap M, Molnar D, et al. Carnitine administration ameliorates the changes in energy metabolism caused by short-term pivampicillin medication. *Eur J Pediatr* 1997;156(10):795-799.
- Mitchell ME. Carnitine metabolism in human subjects: I: normal metabolism. *Am J Clin Nutr* 1978;31(2):293-306. (Review)
- Mitchell ME. Carnitine metabolism in human subjects: II: values of carnitine in biological fluids and tissues of "normal" subjects. *Am J Clin Nutr* 1978;31(3):481-491. (Review)
- Mitchell ME. Carnitine metabolism in human subjects: III: metabolism in disease. *Am J Clin Nutr* 1978;31(4):645-659. (Review)
- Micic S, Lalic N, Nale DJ, et al. Effects of L-carnitine on sperm motility and number in infertile men. *Fertil Steril* 1998;70(3 Suppl 1):S12. (Abstract)
- Mingrone G, Greco AV, Capristo E, et al. L-carnitine improves glucose disposal in type 2 diabetic patients. *J Am Coll Nutr* 1999;18(1): 77-82.
- Moncada ML, Vicari E, Cimino C, et al. Effect of acetylcarnitine treatment in oligoasthenospermic patients. *Acta Eur Fertil* 1992;23:221-224.
- Montgomery SA, Thal LJ, Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. *Int Clin Psychopharmacol* 2003;18(2):61-71.
- Moretti S, Alesse E, Di Marzio L, et al. Effect of L-carnitine on human immunodeficiency virus-1 infection-associated apoptosis: a pilot study. *Blood* 1998;91(10):3817-3824.
- Moretti S, Famularo G, Marcellini S, et al. L-carnitine reduces lymphocyte apoptosis and oxidant stress in HIV-1-infected subjects treated with zidovudine and didanosine. *Antioxid Redox Signal* 2002;4(3):391-403.
- Muller-Tyl E, Lohninger A, Fischl F, et al. The effect of carnitine on sperm count and sperm motility. *Fertilitat* 1988;4:1-4. [German]
- Murakami K, Sugimoto T, Woo M, et al. Effect of L-carnitine supplementation on acute valproate intoxication. *Epilepsia* 1996;37(7): 687-689.
- Murray MT. The many benefits of carnitine. *Am J Natural Med* 1996;3:6-14. (Review)
- Navarro-Quesada FJ, Lluch-Fernandez MD, Vaquero-Abellan M, et al. [Evaluation of the effect of long term valproic acid treatment on plasma levels of carnitine, ammonia and amino acids related to the urea cycle in pediatric epileptic patients.] *Rev Neurol* 1997;25(143):1037-1044. [Spanish]
- Obici S, Feng Z, Arduini A, et al. Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production. *Nat Med* 2003;9(6):756-761.
- Orzali A, Maetzke G, Donzelli F, et al. Effect of carnitine on lipid metabolism in the neonate: II: carnitine addition to lipid infusion during prolonged total parenteral nutrition. *J Pediatr* 1984;104(3):436-440.
- Paradies G, Ruggiero FM, Petrosillo G, et al. Carnitine-acylcarnitine translocase activity in cardiac mitochondria from aged rats: the effect of acetyl-L-carnitine. *Mech Ageing Dev* 1995;84(2):103-112.

Citations and Reference Literature: Carnitine

- Passeri M, Cucinotta D, Bonati PA, et al. Acetyl-L-carnitine in the treatment of mildly demented elderly patients. *Int J Clin Pharmacol Res* 1990;10:75-79.
- Pepine CJ. The therapeutic potential of carnitine in cardiovascular disorders. *Clin Ther* 1991;13(1):2-21; discussion 1. (Review)
- Pistorio E, D'Amico G, Pistorio A. [L-carnitine deficiency.] *Clin Ter* 1996;147(7-8):403-405. [Italian]
- Plioplys AV, Plioplys S. Amantadine and L-carnitine treatment of chronic fatigue syndrome. *Neuropsychobiology* 1997;35:16-23.
- Prasad K. Homocysteine, a risk factor for cardiovascular disease. *Int J Angiol* 1999 Jan;8(1):76-86.
- Pucciarelli G, Mastursi M, Latte S, et al. The clinical and hemodynamic effects of propionyl-L-carnitine in the treatment of congestive heart failure. *Clin Ter* 1992;141:379-384. [Italian; English abstract]
- Raby WN. Carnitine for valproic acid-induced hyperammonemia. *Am J Psychiatry* 1997;154(8):1168-1169.
- Rai G, Wright G, Scott L, et al. Double-blind, placebo controlled study of acetyl-L-carnitine in patients with Alzheimer's dementia. *Curr Med Res Opin* 1990;11:638-647.
- Rebuzzi AG, Schiavoni G, Lanza GA, et al. Rhythm of carnitine levels in serum and urine of normal subjects. *Drugs Exp Clin Res* 1989;15(1):43-46.
- Rose SJ, Stokes TC, Patel S, et al. Carnitine deficiency associated with long-term pivampicillin treatment: the effect of a replacement therapy regime. *Postgrad Med J* 1992;68(805):932-934.
- Rubecz I, Sandor A, Hamar A, et al. Blood levels of total carnitine and lipid utilization with and without carnitine supplementation in newborn infants. *Acta Paediatr Hung* 1984;25(1-2):165-171.
- Sabba C, Berardi E, Antonica G, et al. Comparison between the effect of L-propionylcarnitine, L-acetylcarnitine and nitroglycerin in chronic peripheral arterial disease: a haemodynamic double blind echo-Doppler study. *Eur Heart J* 1994;15(10):1348-1352.
- Sachan DS, Rhew TH, Ruark RA. Ameliorating effects of carnitine and its precursors on alcohol-induced fatty liver. *Am J Clin Nutr* 1984;39(5):738-744.
- Salvioli G, Neri M. L-acetylcarnitine treatment of mental decline in the elderly. *Drugs Exp Clin Res* 1994;20:169-176.
- Sano M, Bell K, Cote L, et al. Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease. *Arch Neurol* 1992;49:1137-1141.
- Sayed-Ahmed MM, Mansour HH, Gharib OA, et al. Acetyl-L-carnitine modulates bleomycin-induced oxidative stress and energy depletion in lung tissues. *J Egypt Natl Cancer Inst* 2004;16(4):237-243.
- Sbriccoli A, Carretta D, Santarelli M, et al. An optimised procedure for prenatal ethanol exposure with determination of its effects on central nervous system connections. *Brain Res Brain Res Protoc* 1999;3(3):264-269.
- Secombe D, Burget D, Frohlich J, et al. Oral L-carnitine administration after jejunoileal by-pass surgery. *Int J Obes* 1984;8(5):427-433.
- Singh RB, Niaz MA, Agarwal P, et al. A randomised, double-blind, placebo-controlled trial of L-carnitine in suspected acute myocardial infarction. *Postgrad Med J* 1996;72:45-50.
- Sorbi S, Forleo P, Fani C, et al. Double-blind, crossover, placebo-controlled clinical trial with L-acetylcarnitine in patients with degenerative cerebellar ataxia. *Clin Neuropharmacol* 2000;23:114-118.
- Spagnoli A, Lucca U, Menasce G, et al. Long-term acetyl-L-carnitine treatment in Alzheimer's disease. *Neurology* 1991;41(11):1726-1732.
- Stadler DD, Bale JF Jr, Chenard CA, et al. Effect of long-term valproic acid administration on the efficiency of carnitine reabsorption in humans. *Metabolism* 1999;48(1):74-79.
- Starling RD, Costill DL, Fink WJ. Relationships between muscle carnitine, age and oxidative status. *Eur J Appl Physiol Occup Physiol* 1995;71(2-3):143-146.
- Sugiyama N, Morishita H, Nagaya S, et al. Biochemical evidence of carnitine effect on propionate elimination. *J Inherited Metab Dis* 1984;7(3):137-138.
- Swamy-Mruthinti S, Carter AL. Acetyl-L-carnitine decreases glycation of lens proteins: in vitro studies. *Exp Eye Res* 1999;69(1):109-115.
- Tamamogullari N, Silig Y, Icagasioglu S, et al. Carnitine deficiency in diabetes mellitus complications. *J Diabetes Complications* 1999;13(5-6):251-253.
- Tepaske R, Velthuis H, Oudemans-van Straaten HM, et al. Effect of preoperative oral immune-enhancing nutritional supplement on patients at high risk of infection after cardiac surgery: a randomised placebo-controlled trial. *Lancet* 2001;358(9283):696-701.
- Terranova R, Luca S. [Treatment of chronic arterial occlusive disease of the lower limbs with propionyl-L-carnitine in elderly patients.] *Minerva Med* 2001;92(1):61-6. [Italian]
- Teri L, Gibbons LE, McCurry SM, et al. Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. *JAMA* 2003;290:2015-2022.
- Thal LJ, Calvani M, Amato A, et al. A 1-year controlled trial of acetyl-L-carnitine in early-onset AD. *Neurology* 2000;55(6):805-810.

Citations and Reference Literature: Carnitine

- Thal LJ, Carta A, Clarke WR, et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. *Neurology* 1996;47:705-711.
- Tishkin VS, Dunaev VV, Kryzhanovskii SA, et al. [Study of anti-ischemic action of carnitine chloride and its effects on the effectiveness of antianginal agents.] *Kardiologiya* 1990;30(10):89-91. [Russian]
- Tolu P, Masi F, Leggio B, et al. Effects of long-term acetyl-L-carnitine administration in rats: I: increased dopamine output in mesocorticolimbic areas and protection toward acute stress exposure. *Neuropsychopharmacology* 2002;27(3):410-420.
- Tomassini V, Pozzilli C, Onesti E, et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. *J Neurol Sci* 2004;218(1-2):103-108.
- Torrioli MG, Vernacotola S, Mariotti P, et al. Double-blind, placebo-controlled study of L-acetylcarnitine for the treatment of hyperactive behavior in fragile X syndrome. *Am J Med Genet* 1999;87:366-368.
- Trappe SW, Costill DL, Goodpaster B, et al. The effects of L-carnitine supplementation on performance during interval swimming. *Int J Sports Med* 1994;15(4):181-185.
- Triggs WJ, Gilmore RL, Millington DS, et al. Valproate-associated carnitine deficiency and malignant cerebral edema in the absence of hepatic failure. *Int J Clin Pharmacol Ther* 1997;35(9):353-356.
- Turpeinen AK, Kuikka JT, Vanninen E, et al. Long-term effect of acetyl-L-carnitine on myocardial 123I-MIBG uptake in patients with diabetes. *Clin Auton Res* 2000;10:13-16.
- Van Oudheusden L, Scholte H. Efficacy of carnitine in the treatment of children with attention-deficit hyperactivity disorder. *Prostaglandins Leukot Essent Fatty Acids* 2002;67:33.
- Vecchi GP, Chiari G, Cipolli C, et al. Acetyl-L-carnitine treatment of mental impairment in the elderly: evidence from a multicenter study. *Arch Gerontol Geriatr* 1991;(Suppl 2):159-168.
- Vermeulen RC, Scholte HR. Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome. *Psychosom Med* 2004;66(2):276-282.
- Vicari E. Effectiveness of a short-term anti-oxidative high-dose therapy on IVF program outcome in infertile male patients with previous excessive sperm radical oxygen species production persistent even following antimicrobials administered for epididymitis: preliminary results: in: International Meeting on Infertility and Assisted Reproductive Technology, Porto Cervo, Italy, June 11-14, 1997. Bologna, Italy: Monduzzi Editore SpA; 1997.
- Vicari E, Cerri L, Cataldo T, et al. Effectiveness of single and combined antioxidant therapy in patients with astheno-necrozoospermia from non-bacterial epididymitis: effects after acetyl-carnitine or carnitine-acetyl-carnitine. The 12th National Conference, Italian Andrology Association. Copanello (CZ), Italy, Jun 9, 1999.
- Vikre-Jorgensen J. [Cardiomyopathy caused by carnitine deficiency.] *Ugeskr Laeger* 1993;155(42):3390-3392. [Danish]
- Vitali G, Parente R, Melotti C. Carnitine supplementation in human idiopathic asthenospermia: clinical results. *Drugs Exp Clin Res* 1995;21:157-159.
- Vukovich MD, Costill DL, Fink WJ. Carnitine supplementation: effect on muscle carnitine and glycogen content during exercise. *Med Sci Sports Exerc* 1994;26(9):1122-1129.
- Werbach MR. Foundations of nutritional medicine. Tarzana, CA: Third Line Press; 1997. (Review)
- Werbach MR. Nutritional strategies for treating chronic fatigue syndrome. *Altern Med Rev* 2000;5(2):93-108. (Review)
- Weschler A, Aviram M, Levin M, et al. High dose of L-carnitine increases platelet aggregation and plasma triglyceride levels in uremic patients on hemodialysis. *Nephron* 1984;38(2):120-124.
- Willner JH, Ginsburg S, DiMauro S. Active transport of carnitine into skeletal muscle. *Neurology* 1978;28:721-724.
- Winter S, Jue K, Prochazka J, et al. The role of L-carnitine in pediatric cardiomyopathy. *J Child Neurol (Canada)* 1995;10(Suppl. 2):2S45-2S51.
- Wolf LR. Adrenergic blocker toxicity. In: Haddad L, Shannon MW, Winchester JF, eds. Clinical management of poisoning and drug overdose. 3rd ed. Philadelphia: WB Saunders; 1998:1031-1040.
- Yesilipek MA, Hazar V, Yegin O. L-Carnitine treatment in beta thalassemia major. *Acta Haematol* 1998;100:162-163.
- Zanardi R, Smeraldi E. A double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia. *Eur Neuropsychopharmacol* 2006;16(4):281-287.